Gemcitabine: immunomodulatory or immunosuppressive role in the tumor microenvironment DOI Creative Commons

Mahnaz Nemati,

Chou‐Yi Hsu, Deepak Nathiya

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: April 9, 2025

Gemcitabine (GEM), a nucleoside analog chemotherapy agent, has been widely used in the treatment of various cancers. In recent years, there growing interest understanding immunomodulatory or immunosuppressive effects GEM. The roles GEM could influence anti-tumor immune responses via several mechanisms, such as modulation antigen presentation, cytokine production, and cell population. Furthermore, is evidence that enhances therapeutic efficacy immunotherapies, including oncolytic viruses, checkpoint inhibitors, CAR T-cells, vaccines. On other hand, accumulating also proposed may act an agent within tumor microenvironment, resulting evasion cells growth. These paradoxical modifying highlight complexity interaction with microenvironment. This review aims to provide overview microenvironment how affects cancer immunotherapy.

Language: Английский

Advancing Natural Killer Cell Therapy: Genetic Engineering Strategies for Enhanced Cancer Immunotherapy DOI Open Access
Joo Dong Park, Ha Eun Shin,

Y. An

et al.

Annals of Laboratory Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 8, 2025

Joo Dong Park, M.S., Ha Eun Shin, Ph.D., Yeon Su An, B.S., Hye Jung Jang, Juwon Se-Na Kim, Chun Gwon and Wooram Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2024.0380

Citations

2
The next frontier in immunotherapy: potential and challenges of CAR-macrophages DOI Creative Commons
Jing Li,

Ping Chen,

Wenxue Ma

et al.

Experimental Hematology and Oncology, Journal Year: 2024, Volume and Issue: 13(1)

Published: Aug. 5, 2024

Abstract Chimeric antigen receptor macrophage (CAR-MΦ) represents a significant advancement in immunotherapy, especially for treating solid tumors where traditional CAR-T therapies face limitations. CAR-MΦ offers promising approach to target and eradicate tumor cells by utilizing macrophages’ phagocytic antigen-presenting abilities. However, challenges such as the complex microenvironment (TME), variability expression, immune suppression limit their efficacy. This review addresses these issues, exploring mechanisms of action, optimal construct designs, interactions within TME. It also delves into ex vivo manufacturing CAR-MΦ, discussing autologous allogeneic sources importance stringent quality control. The potential synergies integrating with existing cancer like checkpoint inhibitors conventional chemotherapeutics are examined highlight possible enhanced treatment outcomes. Furthermore, regulatory pathways scrutinized alongside established protocols cells, identifying unique considerations essential clinical trials market approval. Proposed safety monitoring frameworks aim manage adverse events, cytokine release syndrome, crucial patient safety. Consolidating current research insights, this seeks refine therapeutic applications, overcome barriers, suggest future directions transition from experimental platforms standard care options.

Language: Английский

Citations

12
Immune evasion in ovarian cancer: implications for immunotherapy and emerging treatments DOI
Romi Gupta, Raj Kumar, Courtney A. Penn

et al.

Trends in Immunology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

Citations

1
Immunotherapy and liver transplantation for hepatocellular carcinoma: Current and future challenges DOI

Theodoros Pettas,

Sofia Lachanoudi,

Filippos F. Karageorgos

et al.

World Journal of Transplantation, Journal Year: 2025, Volume and Issue: 15(2)

Published: Feb. 21, 2025

Despite existing curative options like surgical removal, tissue destruction techniques, and liver transplantation for early-stage hepatocellular carcinoma (HCC), the rising incidence mortality rates of this global health burden necessitate continuous exploration novel therapeutic strategies. This review critically assesses dynamic treatment panorama HCC, focusing specifically on burgeoning role immunotherapy in two key contexts: HCC downstaging advanced to facilitate transplant candidacy. It delves into unique immunobiology highlighting tumor-mediated immune evasion mechanisms. Analyzing diverse immunotherapeutic approaches including checkpoint inhibitors, cytokine modulators, vaccines, oncolytic viruses, antigen-targeting antibodies, adoptive cell therapy, acknowledges limitations current diagnostic markers alpha-fetoprotein glypican-3 emphasizes need biomarkers patient selection monitoring. Exploring rationale neoadjuvant adjuvant research is actively exploring safety effectiveness through ongoing clinical trials. The further explores potential benefits challenges combining transplant, careful selection, meticulous monitoring, strategies mitigate post-transplant complications. Finally, latest findings from landscape future directions management, paving way optimizing improving long-term survival patients with challenging malignancy.

Language: Английский

Citations

1
Feeder-cell-free system for ex vivo production of natural killer cells from cord blood hematopoietic stem and progenitor cells DOI Creative Commons

Marta Martin Corredera,

Juliette Paillet, Pierre Gaudeaux

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: Feb. 20, 2025

Natural Killer (NK) cells hold significant promise as therapeutic agents in immuno-oncology due to their ability target and eliminate cancerous infected without causing graft-versus-host disease or cytokine release syndrome. However, the limited availability of robust, scalable methods for generating clinical-grade NK remains a limiting factor broader clinical application. Here we report development novel feeder-cell-free culture system optimized producing from cord blood-derived CD34+ hematopoietic stem progenitor (HSPCs). Our method eliminates need feeder while achieving high yields that exhibit unique marker expression cytotoxic functions. Cord blood HSPCs were cultured our established hDLL 4 generated large numbers human T lymphoid progenitors (ProTcells) 7 days. ProTcells further hDLL4-free, cell differentiation supplemented with cytokines. Following 7- 14-day culture, this produced highly pure populations (>90% CD3-CD56+). Flow mass cytometric analysis confirmed activating receptors, transcription factors (ID2, T-bet) molecules (perforin, granzyme A/B), all essential ProT-NK functionality. These are an immature state, indicated by absence maturation markers (CD16, KIRs). Functional assays demonstrated these capable degranulation cytokines production (TNFα) upon stimulation K562 showed cytotoxicity against superior Peripheral Blood (PB)-NK. In NSG-Tg(hIL-15) mice, colonize bone marrow, liver, spleen persist mature marrow at least 9 days post-injection. Compared D21, D14 was functional homing potential. vivo, anti-tumor assay uses subcutaneous model has potential cells. ex vivo process supports yields, reducing dependency on mitigating contamination risks. findings demonstrate feasibility large, isolated readily available sources offer efficient alternative PB-NK therapies.

Language: Английский

Citations

1
CAR products from novel sources: a new avenue for the breakthrough in cancer immunotherapy DOI Creative Commons
Jiawen Huang, Qian Yang, Wen Wang

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: April 11, 2024

Chimeric antigen receptor (CAR) T cell therapy has transformed cancer immunotherapy. However, significant challenges limit its application beyond B cell-driven malignancies, including limited clinical efficacy, high toxicity, and complex autologous product manufacturing. Despite efforts to improve CAR outcomes, there is a growing interest in utilizing alternative immune cells develop cells. These offer several advantages, such as major histocompatibility (MHC)-independent function, tumor microenvironment (TME) modulation, increased tissue infiltration capabilities. Currently, products from various subtypes, innate cells, hematopoietic progenitor even exosomes are being explored. often show enhanced antitumor diminished superior penetration. With these benefits mind, numerous trials underway access the potential of innovative This review aims thoroughly examine challenges, existing insights on new treatment.

Language: Английский

Citations

5
Immunocyte membrane-derived biomimetic nano-drug delivery system: a pioneering platform for tumour immunotherapy DOI

Y Zeng,

Qing Gu, Dan Li

et al.

Acta Pharmacologica Sinica, Journal Year: 2024, Volume and Issue: 45(12), P. 2455 - 2473

Published: July 31, 2024

Language: Английский

Citations

5
Synthetic Gene Circuits as a Promising Approach in Cancer Immunotherapy DOI

Bhanuprakash Ananthakumar,

Nagashri Nanjundeshwara,

Archana Lakshmaiah

et al.

Advances in medical diagnosis, treatment, and care (AMDTC) book series, Journal Year: 2024, Volume and Issue: unknown, P. 391 - 418

Published: Aug. 28, 2024

Cancer immunotherapy has emerged as a revolutionary approach in the fight against cancer. Unlike traditional treatments like chemotherapy and radiation, harnesses power of body's own immune system to identify destroy cancer cells. promising therapy, but limitations specificity control hinder its full potential. Synthetic gene circuits offer address these challenges. This chapter emphasizes diverse applications synthetic immunotherapy. Additionally, authors discuss advantages AND gate for minimizing off-target effects, engineered bacteria targeted tumour manipulation, T-cell engineering enhanced anti-tumour activity. Ultimately, therapies are not mutually exclusive. While proven effectiveness accessibility, hold immense promise personalized, long-term solutions.

Language: Английский

Citations

5
Recent advances in understanding the immune microenvironment in ovarian cancer DOI Creative Commons
Jinxin Chen, Lu Yang, Yiming Ma

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: June 5, 2024

The occurrence of ovarian cancer (OC) is a major factor in women’s mortality rates. Despite progress medical treatments, like new drugs targeting homologous recombination deficiency, survival rates for OC patients are still not ideal. tumor microenvironment (TME) includes cells, fibroblasts linked to (CAFs), immune-inflammatory and the substances these cells secrete, along with non-cellular components extracellular matrix (ECM). First, TME mainly plays role inhibiting growth protecting normal cell survival. As tumors progress, gradually becomes place promote progression. Immune have attracted much attention as targets immunotherapy. checkpoint inhibitor (ICI) therapy has potential regulate TME, suppressing factors that facilitate advancement, reactivating immune managing growth, extending advanced cancer. This review presents an outline current studies on distinct cellular elements within detailing their main functions possible signaling pathways. Additionally, we examine immunotherapy rechallenge OC, specific emphasis biological reasons behind resistance ICIs.

Language: Английский

Citations

4
CRISPR knock-in of a chimeric antigen receptor into GAPDH 3’UTR locus generates potent B7H3-specific NK-92MI cells DOI
Liujiang Dai, Pengchao Zhang, Xiangyun Niu

et al.

Cancer Gene Therapy, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 20, 2025

Language: Английский

Citations

0